Jean Parker
Corneal and Contact Management · Greensboro, NCNPI 1851555379
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 120 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 14.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,013, 4.9 times the $206 reported in 2019.
Across 120 payments — averaging $25.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$454
- Tarsus Pharmaceuticals, Inc.$373
- Alcon$339
- Oyster Point Pharma, Inc.$311
- AbbVie$295
- Coopervision Inc.$276
- plus $1000 from 12 others
Across 5 payments — averaging $30.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Notal Vision, Inc.$150
What the payments were for
- Food & beverage$3,049100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 19 | $454 |
| Tarsus Pharmaceuticals, Inc. | 14 | $373 |
| Alcon | 12 | $339 |
| Oyster Point Pharma, Inc. | 12 | $311 |
| AbbVie(2 entities) | 13 | $295 |
| Coopervision Inc. | 5 | $276 |
| Novartis | 13 | $214 |
| Biotissue Holdings Inc. | 6 | $173 |
| Harrow Eye, LLC | 4 | $115 |
| Dompe US, Inc. | 5 | $109 |
| Sun Pharmaceutical Industries Inc. | 4 | $85 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $71 |
| Notal Vision, Inc. | 2 | $65 |
| Johnson & Johnson Vision Care, Inc. | 3 | $54 |
| Genentech USA, Inc. | 1 | $46 |
| Shire North American Group Inc | 2 | $31 |
| Kala Pharmaceuticals, Inc. | 1 | $24 |
| ABB Con-cise Optical Group LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few corneal and contact management providers in North Carolinato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 156 | $188,020 |
| LumiganBimatoprost | 75 | $37,830 |
| XiidraLifitegrast | 28 | $33,887 |
| VyzultaLatanoprostene Bunod | 43 | $25,581 |
| Alphagan PBrimonidine Tartrate | 28 | $19,839 |
| Cyclosporine | 24 | $17,268 |
| RocklatanNetarsudil Mesylat/Latanoprost | 26 | $17,091 |
| MieboPerfluorohexyloctane/Pf | 18 | $14,991 |
| TyrvayaVarenicline Tartrate | 22 | $14,118 |
| CequaCyclosporine | 15 | $13,810 |
| RhopressaNetarsudil Mesylate | 12 | $9,992 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 35 | $8,777 |
| Travoprost | 20 | $4,464 |
| Latanoprost | 366 | $4,176 |
| Brimonidine Tartrate | 99 | $3,175 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Alphagan P | $295 | $245,689259 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta, Miebo | $454 | $74,45989 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $311 | $14,11822 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $85 | $13,81015 claims |
| AlconSimbrinza | $339 | $8,77735 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $71 | $84713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few corneal and contact management providers in North Carolinaon file to place this against a meaningful peer group, so we don't.
Other corneal and contact management in Greensboro
- Jingya ChenGreensboro$2K
- Chantel Garcia TarbettHarrisburg$48K
- Hiten PrajapatiMorrisville$7K
- Patrick PattersonBeaufort$6K
- Melissa HeislerWinston Salem$3K
- Kelly ReidWinston Salem$3K
- Linda StolfoRaleigh$2K
- Lisa DavisWinston Salem$801
- Roger DavisWinston Salem$690
- Billy CashWinston-Salem$350
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.